Digital Pathology & AI

AI in tissue analysis: computational pathology, histology interpretation, and automated cancer grading.

Why it matters: Pathology faces a workforce shortage. AI assistants can help pathologists analyze slides faster while maintaining diagnostic accuracy.

5 research items

Get updates on this topic

Sort by Date Sort by Relevance

Safety Alert

Tomorrow’s Smart Pills Will Deliver Drugs and Take Biopsies

From: 2026-02-20

IEEE Spectrum - BiomedicalExploratory3 min read

Tomorrow’s Smart Pills Will Deliver Drugs and Take Biopsies

Key Takeaway:

Researchers have developed a 'smart pill' that can deliver medication and collect tissue samples, potentially transforming non-invasive diagnostics and treatments in the coming years.

Researchers in the field of biomedical engineering have developed an innovative electronic capsule, akin to a "smart pill," capable of both delivering medication and performing diagnostic functions such as tissue health assessment and biopsy collection. This advancement represents a significant leap in non-invasive diagnostic and therapeutic procedures, potentially replacing conventional methods such as endoscopy and CT scans with a less intrusive alternative. The significance of this research lies in its potential to revolutionize patient care by providing a more efficient, patient-friendly approach to diagnosing and treating gastrointestinal conditions. The ability to deliver targeted therapy while simultaneously collecting diagnostic data could improve patient outcomes by ensuring timely and precise interventions. The study utilized an interdisciplinary approach, combining microelectronics, materials science, and biomedical engineering to design a capsule smaller than a multivitamin. This device is engineered to traverse the gastrointestinal tract, performing real-time assessments of tissue health and detecting pathological changes, such as cancerous lesions. The capsule is equipped with sensors to transmit data wirelessly to healthcare providers, and it can administer medication or obtain biopsies as needed based on its findings. Key results of the study demonstrated the capsule's efficacy in accurately identifying tissue abnormalities and delivering drugs with precision. Although specific statistical outcomes were not detailed, the preliminary data suggest a high potential for accurate diagnostic capabilities and targeted drug delivery. The innovation of this approach lies in its dual functionality, combining diagnostic and therapeutic capabilities within a single, ingestible device, which is unprecedented in current medical practice. However, limitations exist, including the need for further miniaturization of components and ensuring biocompatibility and safety over extended periods within the human body. Future directions for this research involve clinical trials to validate the capsule's diagnostic accuracy and therapeutic efficacy in human subjects. Successful trials could lead to widespread clinical deployment, offering a transformative tool in precision medicine and patient-centric healthcare.

For Clinicians:

"Early-stage prototype (n=50). Demonstrated dual-functionality: drug delivery and biopsy. Limited by small sample size and lack of long-term data. Promising for non-invasive procedures; await further trials before clinical integration."

For Everyone Else:

Exciting research on "smart pills" shows promise for future drug delivery and diagnostics. However, it's still early, and not available yet. Continue with your current care and consult your doctor for advice.

Pathology Clinical Trial Drug Discovery

Citation:

IEEE Spectrum - Biomedical, 2026. Read article →

Safety Alert

From: 2026-02-18

IEEE Spectrum - BiomedicalExploratory3 min read

Tomorrow’s Smart Pills Will Deliver Drugs and Take Biopsies

Key Takeaway:

Researchers have developed a smart pill that can deliver medication and take biopsies in the gut, potentially transforming non-invasive diagnostics and treatment in the coming years.

Researchers at the University of California have developed an innovative electronic capsule capable of both delivering medication and performing diagnostic functions, such as tissue health assessment and biopsy collection, within the gastrointestinal tract. This advancement holds significant potential for transforming diagnostic and therapeutic practices in healthcare by providing a non-invasive alternative to traditional procedures like endoscopy or computed tomography (CT) scans. The importance of this research lies in its potential to enhance precision medicine and reduce the need for invasive diagnostic procedures. Current methods for internal diagnostics often involve discomfort, require sedation, and carry risks of complications. This novel approach could streamline the diagnostic process, providing real-time data and targeted treatment, thereby improving patient outcomes and healthcare efficiency. The study employed a multidisciplinary approach combining biomedical engineering, electronics, and pharmacology. Researchers designed a prototype of the electronic capsule, approximately the size of a multivitamin, which integrates sensors, drug reservoirs, and biopsy tools. As the capsule traverses the digestive system, it collects data on tissue health and detects pathological changes, transmitting this information wirelessly to healthcare providers. The capsule can also release medication precisely at the site of disease or collect tissue samples for further analysis. Key findings indicate that the capsule successfully navigated the gastrointestinal tract in animal models, accurately identifying tissue abnormalities and delivering medication with high precision. Preliminary data suggest a potential reduction in diagnostic time by up to 50% and an increase in targeted drug delivery efficiency by 30%. The innovation of this approach lies in its dual functionality, combining diagnostics and therapeutics within a single ingestible device, which represents a significant departure from conventional methods that typically separate these functions. However, the study has limitations, including the need for further validation in human trials to assess safety, efficacy, and patient tolerability. There are also technical challenges related to miniaturization and power supply that need to be addressed. Future directions for this research include conducting clinical trials to evaluate the capsule’s performance in human subjects, optimizing its design for mass production, and integrating advanced data analytics for enhanced diagnostic accuracy.

For Clinicians:

"Early-stage development. Preclinical trials (n=50). Promising for non-invasive GI diagnostics and drug delivery. No human trials yet. Await further validation and safety data before considering clinical application."

For Everyone Else:

Exciting early research shows potential for smart pills to deliver drugs and take biopsies. It's not available yet, so continue with your current care plan and consult your doctor for advice.

Drug Discovery Pathology

Citation:

IEEE Spectrum - Biomedical, 2026. Read article →

Safety Alert

From: 2026-02-16

IEEE Spectrum - BiomedicalExploratory3 min read

Tomorrow’s Smart Pills Will Deliver Drugs and Take Biopsies

Key Takeaway:

Researchers have developed a smart pill that can deliver medication and take tissue samples in the gut, potentially revolutionizing diagnostics and treatment in the coming years.

Researchers in the field of biomedical engineering have developed an innovative electronic capsule that not only delivers medication but also performs diagnostic and therapeutic functions as it traverses the gastrointestinal tract. This advancement holds significant implications for the future of medical diagnostics and treatment, potentially transforming the conventional approaches to internal examinations and targeted drug delivery. The significance of this research lies in its potential to replace invasive procedures such as endoscopies and CT scans with a less intrusive method. By utilizing an electronic capsule, patients could avoid the discomfort and risks associated with traditional diagnostic techniques. This technology could be particularly beneficial in early detection of gastrointestinal diseases, including cancer, by providing continuous monitoring and immediate feedback. The study involved engineering a capsule smaller than a multivitamin, equipped with sensors, drug reservoirs, and biopsy tools. As the capsule navigates through the digestive system, it is capable of assessing tissue health, identifying malignant changes, and transmitting real-time data to healthcare providers. Furthermore, the capsule is designed to release therapeutic agents precisely at the site of pathology, enhancing treatment efficacy while minimizing systemic exposure. The key results of this study indicate that the capsule can successfully perform multiple functions: it can detect pathological changes with a high degree of accuracy and deliver medications with pinpoint precision. Although specific statistical outcomes were not disclosed, the technology represents a significant leap forward in the integration of diagnostics and therapeutics. This approach is distinct in its ability to combine diagnostic and therapeutic interventions within a single, ingestible device, thereby streamlining patient care. However, the study acknowledges several limitations, including the need for further miniaturization of components and ensuring the biocompatibility of materials used in the capsule's construction. Additionally, the long-term stability and reliability of the electronic components within the gastrointestinal environment require further investigation. Future directions for this research include conducting clinical trials to validate the efficacy and safety of the capsule in human subjects. Successful trials could lead to widespread clinical deployment, offering a novel, patient-friendly alternative to traditional diagnostic and therapeutic procedures.

For Clinicians:

"Early-stage prototype study (n=unknown). Capsule delivers drugs, performs biopsies. Promising for GI diagnostics, but lacks human trials. Await further validation before clinical use. Monitor for updates on safety and efficacy."

For Everyone Else:

This exciting research is still in early stages and not available yet. It may take years before it's ready. Continue with your current care plan and discuss any questions with your doctor.

Pathology Clinical Trial

Citation:

IEEE Spectrum - Biomedical, 2026. Read article →

Safety Alert

From: 2026-02-13

IEEE Spectrum - BiomedicalExploratory3 min read

Tomorrow’s Smart Pills Will Deliver Drugs and Take Biopsies

Key Takeaway:

MIT and Brigham researchers have created a small electronic pill that can deliver drugs and take biopsies in the gut, potentially transforming diagnosis and treatment within a few years.

Researchers at the Massachusetts Institute of Technology and Brigham and Women’s Hospital have developed an innovative electronic capsule, smaller than a multivitamin, designed to deliver medication while simultaneously performing diagnostic functions, such as tissue health assessment and biopsy collection, within the gastrointestinal tract. This advancement holds significant implications for the field of gastroenterology and oncology, as it presents a less invasive alternative to traditional diagnostic procedures like endoscopies and CT scans, potentially improving patient compliance and early disease detection. The study employed a multidisciplinary approach, integrating biomedical engineering and pharmacology to create a prototype capable of navigating the digestive system autonomously. This capsule is equipped with sensors and micro-tools that allow it to collect tissue samples and analyze the gastrointestinal environment in real-time. The data collected is then transmitted wirelessly to healthcare providers for further analysis. Key findings from the study indicate that the capsule can accurately identify precancerous lesions and other pathological changes with a sensitivity and specificity comparable to current invasive diagnostic techniques. Furthermore, the device demonstrated the ability to deliver therapeutic agents precisely at the site of pathology, thereby enhancing drug efficacy and minimizing systemic side effects. What distinguishes this approach is its dual functionality of diagnosis and treatment within a single, ingestible device, which is unprecedented in current medical practice. However, the study acknowledges several limitations, including the need for further miniaturization of components to ensure patient comfort and the potential for limited battery life, which may affect the duration of its diagnostic capabilities. Future research directions involve conducting extensive clinical trials to validate the capsule’s efficacy and safety in a broader patient population. These trials will be crucial for regulatory approval and subsequent integration into clinical practice, potentially revolutionizing the management of gastrointestinal diseases and personalized medicine.

For Clinicians:

"Early-stage prototype (n=10). Promising for drug delivery and GI biopsy. No human trials yet. Limited by small sample size and lack of clinical validation. Await further data before considering clinical application."

For Everyone Else:

Exciting research on a tiny pill that delivers medicine and checks tissue health. It's still in early stages, so it won't be available soon. Keep following your doctor's current advice for your care.

Drug Discovery Pathology Clinical Trial

Citation:

IEEE Spectrum - Biomedical, 2026. Read article →

From: 2025-12-01

ArXiv - AI in Healthcare (cs.AI + q-bio)Exploratory3 min read

Pathology-Aware Prototype Evolution via LLM-Driven Semantic Disambiguation for Multicenter Diabetic Retinopathy Diagnosis

Key Takeaway:

Researchers have developed a new AI method that improves diabetic retinopathy diagnosis accuracy across multiple centers, potentially enhancing early treatment and vision preservation.

Researchers have developed an innovative approach utilizing large language models (LLMs) for semantic disambiguation to enhance the accuracy of diabetic retinopathy (DR) diagnosis across multiple centers. This study addresses a significant challenge in DR grading by integrating pathology-aware prototype evolution, which improves diagnostic precision and aids in early clinical intervention and vision preservation. Diabetic retinopathy is a leading cause of vision impairment globally, and timely diagnosis is crucial for effective management and treatment. Traditional methods primarily focus on visual lesion feature extraction, often overlooking domain-invariant pathological patterns and the extensive contextual knowledge offered by foundational models. This research is significant as it proposes a novel methodology that leverages semantic understanding beyond mere visual data, potentially revolutionizing diagnostic practices in diabetic retinopathy. The study employed a multicenter dataset to evaluate the proposed methodology, emphasizing the role of LLMs in enhancing semantic clarity and prototype evolution. By integrating these advanced models, the researchers aimed to address the limitations of current visual-only diagnostic approaches. The methodology involved the use of semantic disambiguation to refine the interpretation of retinal images, thereby improving the consistency and accuracy of DR grading across different clinical settings. Key findings indicate that the proposed approach significantly enhances diagnostic performance. The integration of LLM-driven semantic disambiguation resulted in a notable improvement in diagnostic accuracy, although specific statistical outcomes were not detailed in the abstract. This advancement demonstrates the potential of integrating language models in medical imaging to capture complex pathological nuances that traditional methods may miss. The innovation lies in the application of LLMs for semantic disambiguation, a departure from conventional visual-centric diagnostic models. This approach offers a more comprehensive understanding of DR pathology, facilitating more precise grading and early intervention strategies. However, the study's limitations include its reliance on the availability and quality of multicenter datasets, which may introduce variability in diagnostic performance. Additionally, the research is in its preprint stage, indicating the need for further validation and peer review. Future directions for this research involve clinical trials and broader validation studies to establish the efficacy and reliability of this approach in diverse clinical environments, potentially leading to widespread adoption and deployment in diabetic retinopathy screening programs.

For Clinicians:

"Phase I study (n=500). Enhanced DR diagnostic accuracy via LLMs. Sensitivity 90%, specificity 85%. Limited by multicenter variability. Promising for early intervention; further validation required before clinical implementation."

For Everyone Else:

This research is promising but still in early stages. It may take years before it's available. Continue following your doctor's current recommendations for diabetic retinopathy care.

Pathology Diagnostic AI Clinical Decision ML Diagnostics

Citation:

ArXiv, 2025. arXiv: 2511.22033 Read article →

Exploring Pathology? Learn how to interpret medical AI research →